387 related articles for article (PubMed ID: 24385120)
1. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
3. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
[TBL] [Abstract][Full Text] [Related]
4. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
8. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
[TBL] [Abstract][Full Text] [Related]
9. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
Thiboutot DM; Fleischer AB; Del Rosso JQ; Rich P
J Drugs Dermatol; 2009 Jul; 8(7):639-48. PubMed ID: 19588640
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
12. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
13. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea.
Dahl MV; Jarratt M; Kaplan D; Tuley MR; Baker MD
J Am Acad Dermatol; 2001 Nov; 45(5):723-30. PubMed ID: 11606923
[TBL] [Abstract][Full Text] [Related]
14. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.
Fowler J; Tan J; Jackson JM; Meadows K; Jones T; Jarratt M; Leoni M;
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):474-81. PubMed ID: 25074756
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Kuang AW; DuBois J; Attar M; Ahluwalia G
J Drugs Dermatol; 2018 Feb; 17(2):213-220. PubMed ID: 29462230
[TBL] [Abstract][Full Text] [Related]
16. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea.
Wolf JE; Del Rosso JQ
Cutis; 2007 Jan; 79(1):73-80. PubMed ID: 17330626
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
18. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
Elewski BE; Fleischer AB; Pariser DM
Arch Dermatol; 2003 Nov; 139(11):1444-50. PubMed ID: 14623704
[TBL] [Abstract][Full Text] [Related]
19. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Del Rosso JQ
J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S44-56. PubMed ID: 24229637
[TBL] [Abstract][Full Text] [Related]
20. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Patel NU; Shukla S; Zaki J; Feldman SR
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]